Angitia Biopharmaceuticals has u | Angitia Biopharmaceuticals has unveiled its second mega-round in 14 months, revealing a $130 million series D financing that positions the biotech to take three bone disease prospects deeper into the clinic.

Angitia Biopharmaceuticals to present data on AGA2115 for Osteogenesis Imperfecta at ASBMR 2025.

AGA111 treatment resulted in high spinal fusion success rate and improved functional outcomesWOODLAND HILLS, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Angitia Biopharmaceuticals, a global, clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases, today announced the presentation of data from its randomized, double-blind, placebo-controlled Phase 1/2 study evaluating AGA111 for use in spinal fusion procedures on March 12, 2025, at the 2025 American Academy of Orthopedic Surgeons (AAOS) Annual Meeting in San Diego, California.In the study, treatment with AGA111, a recombinant human bone morphogenetic protein 6 (rhBMP6), led to faster radiographic fusion and a higher fusion success rate, as well as greater improvements in functional outcomes as assessed by the Oswestry Disability Index (ODI) and pain visual analog scale (VAS), compared to placebo.“We are honored and excited to present the full dataset from our Phase 1/2 study of AGA111, representing a rare and valuable randomized, placebo-controlled study in the field of orthopedics and spinal fusion,” said Willard Dere, M.D., Chief Medical Officer of Angitia. “Based on these encouraging results, we are now executing a registrational Phase 3 study of AGA111, which we believe has the potential to significantly accelerate bony fusion and meaningfully improve patient outcomes following spinal fusion surgery.”The Phase 1/2 trial was a randomized, double-blind, placebo-controlled study enrolling 63 patients with degenerative disc disease (DDD) requiring single-level Transforaminal Lumbar Interbody Fusion (TLIF) surgery. Patients were randomized 1:1:1 to 1 of 3 groups: placebo, 0.25mg AGA111, or 0.5mg AGA111. AGA111 or placebo was mixed with autologous blood to create a coagulum, which was then administered into the interbody area during TLIF surgery. No bovine material was used in the treatment or placebo arms. Blinded adjudicators assessed fusion success using CT scan images and hyperflexion/hyperextension X-rays at Months 3, 6, and 12